Skip to the page

Data / Drug companies / Rottendorf Pharma GmbH

Rottendorf Pharma GmbH: 17 products in the FDA NDC directory, labeler code 49629

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Rottendorf Pharma GmbH (labeler code 49629) lists 17 products in the FDA National Drug Code Directory. By type: 17 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on November 22, 2024.

The request: Watch Rottendorf Pharma GmbH (FDA labeler code 49629): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
49629
Products in commercial distribution
17
Packages
22
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
August 2, 2004
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing17100%

Products by type

TypeProductsShare
Drugs for further processing17100%

Dosage forms

Dosage formProductsShare
Tablet1164.7%
Tablet, film coated423.5%
Capsule, gelatin coated15.9%
Pellet15.9%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Acoramidis hydrochloride49629-046Tablet, film coatedDrugs for further processingNovember 22, 2024
Lenacapavir sodium49629-042Tablet, film coatedDrugs for further processingDecember 22, 2022
Sodium phenylbutyrate49629-043PelletDrugs for further processingAugust 11, 2022
Empagliflozin49629-034TabletDrugs for further processingSeptember 1, 2020
Empagliflozin49629-033TabletDrugs for further processingSeptember 1, 2020
Telmisartan and hydrochlorothiazide49629-032TabletDrugs for further processingMay 1, 2020
Telmisartan and hydrochlorothiazide49629-031TabletDrugs for further processingMay 1, 2020
Telmisartan and hydrochlorothiazide49629-030TabletDrugs for further processingMay 1, 2020
Bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate49629-024TabletDrugs for further processingFebruary 7, 2018
Emtricitabine and tenofovir alafenamide fumarate49629-026TabletDrugs for further processingApril 4, 2016
Emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate49629-017TabletDrugs for further processingMarch 1, 2016
Tacrolimus49629-022TabletDrugs for further processingJuly 1, 2015
Tacrolimus49629-021TabletDrugs for further processingJuly 1, 2015
Tacrolimus49629-020TabletDrugs for further processingJuly 1, 2015
Emtricitabine, rilpivirine hydrochloride and tenofovir disoproxil fumarate49629-014Tablet, film coatedDrugs for further processingAugust 10, 2011
Tamsulosin hydrochloride49629-011Capsule, gelatin coatedDrugs for further processingApril 27, 2010
Emtricitabine and tenofovir disoproxil fumarate49629-010Tablet, film coatedDrugs for further processingAugust 2, 2004

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.